EQRx, Inc. (NASDAQ:EQRX – Get Rating) saw an uptick in trading volume on Monday . 148,720 shares traded hands during mid-day trading, a decline of 92% from the previous session's volume of 1,765,429 shares.The stock last traded at $5.34 and had previously closed at $5.14.
Analysts Set New Price Targets
A number of research firms have weighed in on EQRX. JPMorgan Chase & Co. began coverage on shares of EQRx in a research note on Tuesday, August 16th. They issued a "neutral" rating and a $5.50 target price on the stock. The Goldman Sachs Group started coverage on shares of EQRx in a research note on Monday, June 13th. They set a "buy" rating and a $8.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $6.37.
Get EQRx alerts:EQRx Stock Performance
The stock's 50 day moving average is $5.09 and its 200 day moving average is $4.57.
Institutional Trading of EQRx
Institutional investors have recently modified their holdings of the business. Pictet Asset Management SA bought a new stake in EQRx during the 2nd quarter worth approximately $49,000. Prudential Financial Inc. bought a new stake in EQRx during the 2nd quarter worth approximately $53,000. Exos Asset Management LLC bought a new stake in EQRx during the 4th quarter worth approximately $59,000. Virtu Financial LLC bought a new stake in EQRx during the 1st quarter worth approximately $64,000. Finally, Advisor Group Holdings Inc. bought a new stake in EQRx during the 4th quarter worth approximately $67,000. 80.38% of the stock is currently owned by hedge funds and other institutional investors.EQRx Company Profile
(Get Rating)
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
Featured Articles
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.